Clinical Study

A Phase II/III Randomized Trial Of Veliparib Or Placebo In Combination With Adjuvant Temozolomide In Newly Diagnosed Glioblastoma With Mgmt Promoter

Posted Date: May 15, 2019

  • Investigator: Rekha Chaudhary
  • Specialties:
  • Type of Study: Drug

The purpose of this study is to compare the effects, good or bad of the usual treatment (temozolomide) with or without the addition of the investigational drug veliparib for people whose brain tumors show a change in a small region of DNA (gene) called O6-methylguanine methyltransferase (MGMT). Your


To Be Eligible To Participate, Patients Must Have A Type Of Brain Tumor Called A Glioblastoma Multif


Cancer, Glioblastoma, Mgmt Promoter Hyperm, A071102, Brain Tumor

For More Information:

Uc Cancer Institute

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.